David McIntosh: The Evolving Safety Framework for Plasma-Derived Therapies
David McIntosh, Founder and Chair of United Plasma Action, shared Plasma Protein Therapeutics Association’s post on LinkedIn:
“This interesting piece of work will be of significant interest to anyone working in, or interested in, this field of life-saving medicines.
A footnote to add is that what is being described is the 80 percent of current World supplies of plasma that are achieved via Voluntary Reasonably Compensated Donation (VRCD).
Plasma obtained via so-called ‘Unpaid Donation’ almost certainly generates similar results, but as there is so much less of it in the World, relevant data is more scarce.
What is certainly clear, from the vast body of evidence gathered throughout the years of this Century, is that VRCD plasma collection is as safe as, if not safer than, unpaid donor plasma.
As safe – and much more of it – is surely a winning formula!”
Plasma Protein Therapeutics Association (PPTA) shared a post on LinkedIn about a recent article by Halide Tuna et al, published in Annals of Blood, adding:
“A new peer-reviewed publication authored by PPTA’s Halide Tuna and Dr. Toby Simon explores how plasma-derived medicinal products have achieved today’s strong safety profile.
The publication in Annals of Blood highlights the evolution of the ‘safety tripod’ — donor screening, testing, and pathogen reduction — and its role in ensuring the continued safety of plasma-derived therapies.
The conclusion is clear: strong, science-driven systems continue to protect patients today, while ongoing surveillance, periodic evaluation of methods, and technological innovations are essential for future preparedness.”
Title: Plasma-derived medicinal products: a narrative review of the multi-layered approach to ensuring pathogen safety
Authors: Halide Tuna, Toby Simon

Other posts featuring David McIntosh on Hemostasis Today.
-
Nov 18, 2026, 01:45Shikha Jha: My Takeaways from the 4th GANSID International Congress
-
Nov 18, 2026, 01:34Zeeshan Ahmed Khattak: Treatment of Fever and Neutropenia in Hematology/Oncology and Hematopoietic Cell Transplant Patients
-
Nov 17, 2026, 23:45Cajetan Reichardt: LAAO vs. OAC in AF – Balancing Nonprocedural Bleeding and Ischemic Stroke Risk
-
Nov 17, 2026, 23:42Brian Tegtmeyer: Expanding Pre-Hospital Administration of Low-Titer O Positive Whole Blood
-
Nov 17, 2026, 23:41Mansi Kala: Advancing Hematology – From Evidence to Clinical Excellence
-
Nov 17, 2026, 23:40Nathan Connell: Registered for the WFH Comprehensive Care Summit 2027 in Prague
-
Nov 17, 2026, 23:38Yaariv Khaykin: Does Reducing AF Burden After Ablation Change the Need for Anticoagulation?
-
Nov 17, 2026, 23:38Amos Gitonga Mbaabu: Strengthening Care and Advocacy for Haemophilia and SCD across Southern Africa
-
Nov 17, 2026, 23:35Muhammad Sameed Altaf: A Decade of Working Together for Thalassemia Awareness and Patient Support